Genomic landscape of treatment refractory metastatic colorectal cancer

R L Eefsen, K S Simonsen, P Grundtvig, L Klarskov, I M Chen, D Høgdall, B V Jensen, T Lorentzen, T S Poulsen, S Theile, D Nielsen, E Høgdall

Abstract

BACKGROUND: Metastatic colorectal cancer (mCRC) is a complex and heterogeneous disease with few standard and targeted treatment options. Next-generation sequencing of tumor tissue was performed to identify cancer driver mutations to discover possible personalized treatment options, as targeted treatment possibilities are limited for this patient population. Results of genomic sequencing in patients with treatment-refractory mCRC are described in this retrospective analysis.

MATERIAL AND METHODS: Clinico-pathological characteristics and genomic sequence results of consecutive patients with refractory mCRC, referred to the Experimental Cancer Therapy Unit (ECTU) at Department of Oncology, Herlev & Gentofte Hospital in the period from 1 October 2015 to 14 December 2018 were reviewed in this retrospective analysis. Tumor tissue from the patients was analyzed by next-generation sequencing using the Oncomine Comprehensive primer panel to detect actionable variants of cancer driver mutations and microsatellite instability status. From August 2018 tumor mutational burden was also analyzed.

RESULTS: A total of 80 patients with treatment-refractory mCRC and in a fairly good performance were referred to the ECTU during this period. Genomic sequencing of tumor tissue was performed for all 80 patients and a cancer driver mutation was identified in 90% (n = 72) of the patients. A total of 31.3% (n = 25) of the patients received therapy either as targetable therapy outside an available trial (n = 2), FDA approved therapy (n = 2), or treatment in phase 1 or 2 trials, independent of the genomic signature 26.3% (n = 21).

CONCLUSION: Most mCRC patients refractory to standard anti-neoplastic therapies, presented with a cancer driver mutation, however, only a few of these mutations gave rise to matched therapies as only 2.5% of the patients from this period received targeted therapy.

OriginalsprogEngelsk
TidsskriftActa Oncologica
Vol/bind60
Udgave nummer12
Sider (fra-til)1621-1628
Antal sider8
ISSN0284-186X
DOI
StatusUdgivet - dec. 2021

Fingeraftryk

Dyk ned i forskningsemnerne om 'Genomic landscape of treatment refractory metastatic colorectal cancer'. Sammen danner de et unikt fingeraftryk.

Citationsformater